ALX Oncology Holdings Inc. (ALXO)
ALXO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2022-12-31, https://www.sec.gov/Archives/edgar/data/1810182/000095017023007013/0000950170-23-007013-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2022-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ALXO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001810182 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2022
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$123.5M |
| Operating income | -$127.4M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $48.8M |
| Total assets | $306.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-08-06 |
| Cash and burn | $22.7M cash; operating cash flow -$17.7M a quarter. | Report 2026-06-30 |
| Shares outstanding | 138,276,997 (2026-07-30); 53,551,134 a year earlier; 41,151,819 three years earlier. | Cover page 2026-07-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns | Latest 2026-01-30 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, San Francisco, California, United States | PCAOB Form AP 2026-03-31 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $5.0M, sold $43K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$18.0M | -$16.1M | $22.7M | $10.2M | Needs four quarters | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | Not filed | -$17.9M | -$18.6M | $32.3M | $8.9M | Needs four quarters | 10-Q 2026-08-06 |
| Q4 2025 2025-12-31 | Not filed | -$22.8M | -$19.0M | $16.4M | $10.2M | Needs four quarters | 10-K 2026-03-09 |
| Q3 2025 2025-09-30 | Not filed | -$22.1M | -$17.1M | $23.4M | $10.6M | Needs four quarters | 10-Q 2025-11-07 |
| Q2 2025 2025-06-30 | Not filed | -$25.9M | -$23.4M | $19.3M | $10.6M | Needs four quarters | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | Not filed | -$30.8M | -$24.7M | $20.6M | $10.6M | Needs four quarters | 10-Q 2026-08-06 |
| Q4 2024 2024-12-31 | Not filed | -$29.2M | -$32.0M | $17.6M | $10.6M | Needs four quarters | 10-K 2026-03-09 |
| Q3 2024 2024-09-30 | Not filed | -$30.7M | -$25.4M | $16.1M | $10.6M | Needs four quarters | 10-Q 2025-11-07 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-01-30 |
| Latest annual report | 10-K | 2026-03-09 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEF 14A | 2026-04-20 |
Source: SEC EDGAR submissions feed, 422 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -10.0% |
| 1 month | +6.1% |
| 3 months | -46.4% |
| Year to date | -8.0% |
| 1 year | -14.8% |
| From 52-week high | -60.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AKBA | Akebia Therapeutics Inc. | $0.4486 | -5.40% | $124.6M |
| SPRB | Spruce Biosciences Inc. | $42.25 | -2.45% | $121.4M |
| CNTN | Canton Strategic Holdings Inc. | $1.64 | -4.09% | $130.7M |
| NTHI | NeOnc Technologies Holdings Inc. | $4.54 | -7.54% | $131.0M |
| UPB | Upstream Bio Inc. | $2.15 | -22.66% | $117.8M |
| MENS | Jyong Biotech Ltd. | $1.77 | +0.57% | $134.6M |
| IMUX | Immunic Inc. | $7.23 | -3.86% | $114.8M |
| MSLE | Satellos Bioscience Inc. | $6.47 | -2.34% | $137.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier